Research advances on TIL therapy for colorectal cancer

• Jiaojiao Jiang ^[1] ; Wenxi Shu ^[1] ; Qinghua Yao ^[2]
  1. [1] Zhejiang Chinese Medical University

     Zhejiang Chinese Medical University

     China

     
  2. [2] The Second Affiliated Hospital of Zhejiang Chinese Medical University, Xinhua Hospital of Zhejiang Province, Hangzhou, Zhejiang, China
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 26, Nº. 12, 2024, págs. 2917-2923
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Colorectal cancer (CRC) is a prevalent gastrointestinal malignancy. Tumor-infiltrating lymphocyte (TIL) therapy, a form of adoptive cellular therapy (ACT), involves isolating T lymphocytes from tumor tissues, in vitro expansion, and reintroduction into the body to target and eliminate tumor cells. This article presents an overview of the development and application of TIL therapy in CRC, as well as the associated challenges.